Training and Resources

KEYTRUDA^® (pembrolizumab)

General Itemtypeofcontent|therapeuticgroup|localproductname|otherother|Oncology|Keytruda|general04550tcm:4244-693520KEYTRUDA® (pembrolizumab) Mode of Action/static/mciuk/images/keytruda_moa@2x.png/training-resources/keytruda/moa.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda_moa@2x.pngpublishDateTime2021-02-01T14:36:14assetIdtcm:4244-693520pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsMOA,Mode of action,Dual ligand blockade,anti-PD1,Non-small cell lung cancer,NSCLC,Keytruda,pembrolizumab,immunotherapyspecialityexpirationdatehotpublicationdate2018-11-06codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionThis page contains video information on the mode of action for KEYTRUDA▼ (pembrolizumab) and is intended only for UK Healthcare Professionals.asset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1039566KEYTRUDA® (pembrolizumab) in combination with chemotherapy: proposed mode of action video/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.png/training-resources/keytruda/keytruda-in-combination-moa.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.pngpublishDateTime2021-08-04T15:25:16assetIdtcm:4244-1039566pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2019-03-03codextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1093262A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-related adverse events/static/mciuk/images/keytruda-pdf-guide-to-iraes-thumb@2x.png/training-resources/keytruda/guide-to-keytruda.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda-pdf-guide-to-iraes-thumb@2x.pngpublishDateTime2021-08-04T15:25:16assetIdtcm:4244-1093262pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2019-03-04codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeOffsite LinkassetfranchiseOncologyasset_descriptionasset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1149942KEYTRUDA® (pembrolizumab) Metastatic Monotherapy Patient Diary/static/mciuk/images/msdc_keytruda_pan_tumor_diary.png/training-resources/keytruda/mono-patient-diary.xhtml <span class="pi-container" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"><a class="pigb" href="https://www.emcpi.com/pi/33162" target="_blank">Prescribing Information (Great Britain)</a><a class="pini" href="https://www.emcpi.com/pi/ni/378" target="_blank">Prescribing Information (Northern Ireland)</a>[External links]branded/static/mciuk/images/msdc_keytruda_pan_tumor_diary.pngpublishDateTime2021-09-17T13:22:04assetIdtcm:4244-1149942pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2021-07-13codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeOffsite LinkassetfranchiseOncologyasset_descriptionasset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1243064KEYTRUDA® (pembrolizumab) Dosing and Administration/static/mciuk/images/msdc_keytruda_dosing_and_admin_guide_monotherapy.pngKEYTRUDA® (pembrolizumab) Dosing and Administration/static/mciuk/pdf/KEYTRUDA_Dosing_and_administration_guide_for_monotherapy.pdf <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_dosing_and_admin_guide_monotherapy.pngpublishDateTime2021-04-12T08:10:30assetIdtcm:4244-1243064pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2021-03-24codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00

< Previous 1 Next >

General Itemtypeofcontent|therapeuticgroup|localproductname|otherother|Oncology|Keytruda|general04550tcm:4244-693520KEYTRUDA® (pembrolizumab) Mode of Action/static/mciuk/images/keytruda_moa@2x.png/training-resources/keytruda/moa.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda_moa@2x.pngpublishDateTime2021-02-01T14:36:14assetIdtcm:4244-693520pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsMOA,Mode of action,Dual ligand blockade,anti-PD1,Non-small cell lung cancer,NSCLC,Keytruda,pembrolizumab,immunotherapyspecialityexpirationdatehotpublicationdate2018-11-06codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionThis page contains video information on the mode of action for KEYTRUDA▼ (pembrolizumab) and is intended only for UK Healthcare Professionals.asset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1039566KEYTRUDA® (pembrolizumab) in combination with chemotherapy: proposed mode of action video/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.png/training-resources/keytruda/keytruda-in-combination-moa.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.pngpublishDateTime2021-08-04T15:25:16assetIdtcm:4244-1039566pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2019-03-03codextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1093262A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-related adverse events/static/mciuk/images/keytruda-pdf-guide-to-iraes-thumb@2x.png/training-resources/keytruda/guide-to-keytruda.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda-pdf-guide-to-iraes-thumb@2x.pngpublishDateTime2021-08-04T15:25:16assetIdtcm:4244-1093262pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2019-03-04codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeOffsite LinkassetfranchiseOncologyasset_descriptionasset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1149942KEYTRUDA® (pembrolizumab) Metastatic Monotherapy Patient Diary/static/mciuk/images/msdc_keytruda_pan_tumor_diary.png/training-resources/keytruda/mono-patient-diary.xhtml <span class="pi-container" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance"><a class="pigb" href="https://www.emcpi.com/pi/33162" target="_blank">Prescribing Information (Great Britain)</a><a class="pini" href="https://www.emcpi.com/pi/ni/378" target="_blank">Prescribing Information (Northern Ireland)</a>[External links]branded/static/mciuk/images/msdc_keytruda_pan_tumor_diary.pngpublishDateTime2021-09-17T13:22:04assetIdtcm:4244-1149942pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2021-07-13codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeOffsite LinkassetfranchiseOncologyasset_descriptionasset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00tcm:4244-1243064KEYTRUDA® (pembrolizumab) Dosing and Administration/static/mciuk/images/msdc_keytruda_dosing_and_admin_guide_monotherapy.pngKEYTRUDA® (pembrolizumab) Dosing and Administration/static/mciuk/pdf/KEYTRUDA_Dosing_and_administration_guide_for_monotherapy.pdf <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_dosing_and_admin_guide_monotherapy.pngpublishDateTime2021-04-12T08:10:30assetIdtcm:4244-1243064pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatehotpublicationdate2021-03-24codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagsseoUrl00